Chengdu huasun technology group Inc. , LTD. (SZSE:000790) singed a Share Transfer Agreement to acquire a 51% stake in Tibet Kangyu Pharmaceutical Co., Ltd. from Tibet Wan?an Drug Information Consulting Co., Ltd. for CNY 51 million on August 7, 2023. Under the terms, Chengdu huasun technology will pay 20% consideration within 7 working days of the agreement, 20% within 7 working days of completion, 30% within 7 working days from the share delivery date, 10% each within 30 days from the audit report of Tibet Kangyu Pharmaceutical for August to December, 2023, year 2024, and 2025. As of April 30, 2023, Tibet Kangyu Pharmaceutical reported total assets of CNY 167.85 million and net asset of CNY 27.42 million.

The transaction is approved by the board of Chengdu huasun technology and does not need the Shareholders? Approval.